Literature DB >> 17613925

Faecal calprotectin concentrations in untreated coeliac patients.

Massimo Montalto1, Luca Santoro, Valentina Curigliano, Ferruccio D'Onofrio, Giovanni Cammarota, Simona Panunzi, Riccardo Ricci, Antonella Gallo, Antonio Grieco, Antonio Gasbarrini, Giovanni Gasbarrini.   

Abstract

OBJECTIVE: Calprotectin is a granulocyte cytosolic protein that is considered to be a promising marker of subclinical inflammation. High faecal calprotectin concentrations (FCCs) have been found in several intestinal diseases, but no data are currently available on patients with coeliac disease. The purpose of this pilot study was to evaluate FCCs in untreated coeliac patients and to correlate them with clinical score and histological characteristics.
MATERIAL AND METHODS: Twenty-eight consecutive coeliac patients were recruited. Thirty healthy adult volunteers participated as the control group. FCCs were determined by ELISA. Clinical assessment was carried out in all patients. The histological severity of lesions and the infiltration of neutrophil polymorphs in the intestinal mucosa were also evaluated. Mean FCCs in patients and the control group were compared by means of the t-test for independent samples. In coeliac patients, differences in FCCs in subgroups identified by clinical score, lesion severity and neutrophil infiltration were evaluated by the Kruskal-Wallis non-parametric test.
RESULTS: FCCs in untreated coeliac patients were not significantly different from those in controls (p=0.163). Among coeliac patients, FCCs were not significantly different in relation to the level of clinical score, lesion severity or neutrophil infiltration (p=0.92, p=0.96 and p=0.74, respectively).
CONCLUSIONS: This study shows, for the first time, that FCCs in untreated coeliac patients do not differ significantly from those in controls.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17613925     DOI: 10.1080/00365520601173632

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  15 in total

1.  Fecal calprotectin in coeliac disease.

Authors:  Pietro Capone; Antonio Rispo; Nicola Imperatore; Nicola Caporaso; Raffaella Tortora
Journal:  World J Gastroenterol       Date:  2014-01-14       Impact factor: 5.742

2.  Markers of systemic and gut-specific inflammation in celiac disease.

Authors:  Chiara Saroli Palumbo; Jonathan Wyse
Journal:  Turk J Gastroenterol       Date:  2020-02       Impact factor: 1.852

Review 3.  Fecal calprotectin use in inflammatory bowel disease and beyond: A mini-review.

Authors:  Bashaar Alibrahim; Mohammed I Aljasser; Baljinder Salh
Journal:  Can J Gastroenterol Hepatol       Date:  2015-04

4.  The Activity of Antimicrobial Peptides in Pediatric Celiac Disease.

Authors:  Altinoy T Kamilova; Gulnoza K Azizova; Zulkhumar E Umarnazarova; Dilrabo A Abdullaeva; Svetlana I Geller
Journal:  Front Pediatr       Date:  2022-06-06       Impact factor: 3.569

5.  All that glitters is not always gold.

Authors:  E Harrison; S Hayes; L Howell; S Lal
Journal:  BMJ Case Rep       Date:  2014-02-10

6.  Faecal calprotectin in colonic diverticular disease: a case-control study.

Authors:  Antonio Tursi; Giovanni Brandimarte; Walter Elisei; Gian Marco Giorgetti; Cosimo Damiano Inchingolo; Fabio Aiello
Journal:  Int J Colorectal Dis       Date:  2008-10-22       Impact factor: 2.571

Review 7.  Calprotectin: Clinical Applications in Pediatrics.

Authors:  Oscar R Herrera; Michael L Christensen; Richard A Helms
Journal:  J Pediatr Pharmacol Ther       Date:  2016 Jul-Aug

Review 8.  The cystic fibrosis intestine.

Authors:  Robert C De Lisle; Drucy Borowitz
Journal:  Cold Spring Harb Perspect Med       Date:  2013-09-01       Impact factor: 6.915

9.  Value of fecal calprotectin in the evaluation of patients with abdominal discomfort: an observational study.

Authors:  Michael Manz; Emanuel Burri; Claude Rothen; Nuschin Tchanguizi; Christian Niederberger; Livio Rossi; Christoph Beglinger; Frank Serge Lehmann
Journal:  BMC Gastroenterol       Date:  2012-01-10       Impact factor: 3.067

10.  Diagnostic yield of endoscopy in patients with abdominal complaints: incremental value of faecal calprotectin on guidelines of appropriateness.

Authors:  Emanuel Burri; Michael Manz; Patricia Schroeder; Florian Froehlich; Livio Rossi; Christoph Beglinger; Frank Serge Lehmann
Journal:  BMC Gastroenterol       Date:  2014-03-29       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.